The Pharmaceutical Accountability Foundation is taking AbbVie to court in the Netherlands for allegedly overcharging Dutch citizens for rheumatoid arthritis drug Humira, The Financial Times reported.
The foundation said in a statement that AbbVie had abused its dominant position in the market from 2004 to 2018 “to keep prices and profits high”.
Related: AbbVie’s Humira Patent Suit Survives Antitrust Appeal
Wilbert Bannenberg, the PAF’s chair, said: “By making excessive profits, amounting to €68 per Dutch citizen, AbbVie has displaced other healthcare, and thus damaged the health of Dutch citizens.
“No doctor wants to be forced to prioritise one patient [or] treatment over another due to limited budgets.” Lawsuits surrounding access to drugs are nothing new.
The human rights element of the lawsuit brought by PAF against AbbVie is novel because it considers the overall effect of high prices on healthcare and society, even for those who did not directly access the drug, rather than focusing on one single molecule.
Featured News
EU Conducts First-Ever Raids on a Company Under Foreign Subsidies Regulation
Apr 23, 2024 by
CPI
FTC Moves to Ban Non-Compete Agreements, Aiming to Boost Labor Mobility
Apr 23, 2024 by
CPI
Federal Judge Nods at $418M Deal in Real Estate Antitrust Suit
Apr 23, 2024 by
CPI
Mexican Watchdog Probes Amazon and Mercado Libre Over Loyalty Bundles
Apr 23, 2024 by
CPI
Competition Commission of India to Probe AI Landscape for Competition
Apr 23, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI